Researchers presented a scalable lipid nanoparticle production (SCALAR) platform to develop SARS-CoV-2 mRNA lipid nanoparticle vaccines.
GrowGeneration Misses Revenue Forecast and Cuts Outlook
GrowGeneration Reports Second Quarter 2023 Financial Results Net Revenue of $63.9 million Represents a 12% Sequential Improvement from Prior Quarter Net Loss of $5.7 million